38 results about "Uric acid transport" patented technology

The invention belongs to the field of medicinal chemistry and particularly relates to hURAT1 (human urate anion transporter 1) inhibitors and an application thereof. Specifically, the hURAT1 inhibitors are compounds with structure shown as formula (I) or (II) in the description or pharmaceutically acceptable salts of the compounds. Experiments prove that the compounds have good inhibition effect on uric acid transport of the hURAT1 in an HEK293 transfection cell, which shows that the compounds have good application prospect in treatment of hyperuricemia or gout.

The invention relates to application of fisetin in preparation of a medicine for preventing and treating uric acid nephropathy, and belongs to the field of medicine. The invention provides application of fisetin or salt thereof in preparation of the medicine for treating and / or preventing the uric acid nephropathy. Animal experiments prove that the fisetin can regulate protein expression of kidney urate transporters URAT1, OAT1, OAT3 and ABCG2, improve uric acid excretion rate and obviously reduce serum creatinine, blood urea nitrogen and blood uric acid levels, also has an effect of inhibiting renal interstitial fibrosis, can obviously reduce expression quantities of fibrosis-related proteins such as alpha-SMA, cologen I and fibronectin, has an exact prevention / treatment effect on the uric acid nephropathy and provides a new choice for clinical medication.

Novel salts and cocrystals of lesinurad, processes for their preparation, pharmaceutical compositions comprising these new salt forms and co-crystals, and use of them for treating or delaying progression or onset of diseases or disorders related to activity of uric acid transport 1 (URAT1) proteins are disclosed. These novel forms were characterized by X-ray powder diffraction, differential scanning calorimetry, and other techniques. They can be readily prepared and are suitable for preparation of solid dosage forms owing to their ease of handling and superior pharmacological properties.

The invention discloses a DNA fragment for uric acid-induced target protein expression, a related promoter and application. The present invention provides a DNA molecule whose nucleic acid sequence is the 143-200 nucleotides from the 5' end of sequence 1 in the sequence listing. DNA fragments containing the above DNA molecules are also within the scope of the present invention. The experiments of the present invention prove that the present invention obtains a new promoter by transforming the -35 and -10 regions of the lac promoter of Escherichia coli, which can utilize uric acid under the cooperation of the uric acid regulatory protein HucR and the uric acid transporter YgfU Induce the expression of the target protein. Therefore, the promoter and related expression system of the present invention can be used to express the target protein under the induction of uric acid, and can also be used in a biological uric acid detection system.

The invention discloses a 2-[5-bro-4-(4-fluorocyclopropyl-naphthalene-1-base)-4H-1,2,4-triazole-3-sulfenyl] acetate compound with a structure of formula (I), and an acceptable salt on pharmacy, an optical isomer or a prodrug thereof, wherein R1, R2, R3 and R4 respectively independently represents H or F, and R1, R2, R3 and R4 are not all H. By introducing F atoms onto cyclopropyl of lesinurad Sodium, the inhibition activity for urate transporter 1 is greatly improved, no serious side effect presents, and the 2-[5-bro-4-(4-fluorocyclopropyl-naphthalene-1-base)-4H-1,2,4-triazole-3-sulfenyl] acetate compound is particularly suitable for preparing a drug for preventing or treating hyperuricemia.

The invention relates to the field of drugs related to hyperuricemia and gout, particularly to urate transporter 1 inhibitors adopting succinimide structures containing methoxyl naphthalene rings, preparation methods of the urate transporter 1 inhibitors, drug composition containing the urate transporter 1 inhibitors and applications of the urate transporter 1 inhibitors to preparation of diabetes drugs. The structural formula is shown in the specification, wherein R<1> is selected from H and halogen substituents.

The invention relates to the field of medicines related to hyperuricemia and gout. Specifically, the present invention relates to a class of uric acid transporter 1 inhibitors of nitrophenyl substituted naphthalene cyclosuccinic acid amide structures, their preparation methods, pharmaceutical compositions containing them, and their application in the preparation of diabetes drugs . (I ) Wherein, R1 is selected from H and halogen substituents.

The invention relates to a pharmaceutical composition containing a uric acid transport protein inhibitor and a preparation method thereof. Specifically, the pharmaceutical composition contains 1-((6-bromoquinolin-4-yl)thio)cyclobutanecarboxylic acid or a pharmaceutically acceptable salt thereof, and low-substituted hydroxypropyl cellulose, and the pharmaceutical composition The product has good dissolution rate and excellent stability.

The invention relates to the field of medicines related to hyperuricemia and gout, and particularly relates to urate transporter 1 inhibitors having structures of nitronaphthalene-ring-containing butanedioic acid amides, a preparing method thereof, pharmaceutical compositions containing the inhibitors and applications of the inhibitors in preparation of medicines for diabetes. A formula (I) is shown in the specification, wherein R1 is selected from -NO2 and -CN, and R2 is selected from H, C1-C5 alkyl and C3-C6 cycloalkyl.

The invention relates to the field of medicaments associated with hyperuricemia and gout. Specifically, the invention relates to a urate transporter 1 inhibitor with a nitro-substituted triazole sulfinyl malonate structure, a preparation method of the urate transporter 1 inhibitor, a pharmaceutical composition containing the urate transporter 1 inhibitor and application of the urate transporter 1 inhibitor in preparation of diabetic medicaments. The structure is shown in the specification.

The invention relates to the field of medicaments associated with hyperuricemia and gout. Specifically, the invention relates to a urate transporter 1 inhibitor with an alkoxy-substituted triazole sulfinyl malonate structure, a preparation method of the urate transporter 1 inhibitor, a pharmaceutical composition containing the urate transporter 1 inhibitor and application of the urate transporter 1 inhibitor in preparation of diabetic medicaments. The structural formula is shown in the specification, wherein R is selected from H, alkyl of C1-C8 and cycloalkyl of C3-C6.

The invention relates to the field of medicaments which are associated with hyperuricemia and gout and particularly relates to urate transporter 1 inhibitors which contain alkoxyl-substituted triazole sulfonyl propane diacid structures, a preparation method thereof, a pharmaceutical composition containing the urate transporter 1 inhibitors and application of the urate transporter 1 inhibitors in preparation of diabetes drugs. The formulae of the urate transporter 1 inhibitors are shown in the specification, wherein R is selected from H, C1-C8 alkyl and C3-C6 cycloalkyl.